Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
Mvabea suspension for injection.
Ebola vaccine (MVA-BN-Filo [recombinant]).
Pharmaceutical Form |
---|
Suspension for injection. Light yellow, clear to milky suspension. |
One dose (0.5 mL) contains:
Modified Vaccinia Ankara Bavarian Nordic Virus* encoding the:
Zaire ebolavirus (EBOV) Mayinga variant glycoprotein (GP)
Sudan ebolavirus Gulu variant GP
Taï Forest ebolavirus nucleoprotein
Marburg marburgvirus Musoke variant GP
Not less than 0.7 × 108 infectious units (Inf.U)
* Produced in chicken embryo fibroblast cells and by recombinant DNA technology.
This product contains genetically modified organisms (GMOs).
This vaccine contains trace residues of gentamicin (see section 4.3).
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Ebola vaccine |
Ebola vaccine consists of a live, attenuated recombinant vesicular stomatitis virus-based vector expressing the envelope glycoprotein gene of Zaire Ebola virus (rVSV∆G-ZEBOV-GP). Immunisation of subjects with the vaccine results in an immune response and protection from Zaire Ebola Virus Disease (EVD). |
List of Excipients |
---|
Sodium chloride |
0.5 mL suspension in a single-dose Type I glass vial with a rubber stopper (chlorobutyl with fluoropolymer coated surface), aluminium crimp and yellow plastic cap.
Pack size of 20 single-dose vials.
Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
EU/1/20/1445/001
Date of first authorisation: 01 July 2020
Drug | Countries | |
---|---|---|
MVABEA | Estonia, Croatia, Ireland, Italy, Lithuania, Poland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.